Abstract
Antiestrogens are designed to antagonize hormone induced proliferation and ERα target gene expression in mammary tumor cells. Commonly used drugs such as OH-Tamoxifen and ICI 182780 (Fulvestrant) block cell cycle progression in G0/G1. Inversely, the effect of cell cycle stage on ER regulated gene expression has not been tested directly. We show that in ERα-positive breast cancer cells (MCF-7) the estrogen receptor gene and downstream target genes are cell cycle regulated with expression levels varying as much as three-fold between phases of the cell cycle. Steroid free culture conditions commonly used to assess the effect of hormones or antiestrogens on gene expression also block MCF-7 cells in G1-phase when several ERα target genes are overexpressed. Thus, cell cycle effects have to be taken into account when analyzing the impact of hormonal treatments on gene transcription. We found that antiestrogens repress transcription of several ERα target genes specifically in S phase. This observation corroborates the more rapid and strong impact of antiestrogen treatments on cell proliferation in thymidine, hydroxyurea or aphidicolin arrested cells and correlates with an increase of apoptosis compared to similar treatments in lovastatin or nocodazol treated cells. Hence, cell cycle effects synergize with the action of antiestrogens. An interesting therapeutic perspective could be to enhance the action of anti-estrogens by associating hormone-therapy with specific cell cycle drugs.
Highlights
Estrogens play a key role in the development of the mammary gland
We have investigated whether the effect of several commonly used antiestrogens such as OH-TAM and ICI 182.780 (ICI) on estrogen receptor-a (ERa) target gene expression and cell proliferation was dependent on the cell cycle stage
Minimal perturbations of general metabolic functions occurred since the rate of RNA, protein, and initial DNA synthesis were unaffected by Lovastatin [18]
Summary
Estrogens play a key role in the development of the mammary gland. In the normal gland, proliferating cells do not express estrogen receptors. Estrogen receptor-a (ERa) which acts as a ligand (estrogen)-dependent transcription factor is expressed in the majority of mammary tumors (70%). Estrogens bound to ERa regulate target genes implicated in proliferation including CDK2, CDK4, Cyclin D1 (CCND1) or the proto-oncogene c-Myc (MYC) [4,5,6]. Several genes which negatively control cell proliferation such as cyclin G2 (CCG2), caspase 9 (CSP9) or p21 are repressed by estrogens [7,8]. Anti-estrogens such as Tamoxifen (OH-TAM) or ICI 182.780 (ICI) block ERa-positive breast cancer cells in G1 [11,12]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.